Update: A spring in the step as confidence grows
Skyepharma's Q115 trading update shows progress is being maintained, highlighting the strength of the underlying business now that the bonds and other costly loans have been repaid. Demand is growing for flutiform and sales of Solaraze in the US were significantly ahead of expectations. The GSK products continued to build momentum, while Exparel is still expected to trigger the $8m sales milestone this year. We have raised our valuation slightly from £342m or 327p per share, to £354m or 338p a share.Skyland Petroleum is engaged in the licensing of copyright for feature films.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.